or Try an Advanced Search...

    Technical Analysis for AGRX - Agile Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 1.45 0.00% 0.00
    AGRX closed unchanged on Wednesday, August 14, 2024, on 45 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: Nov 7
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Flat Up Up
    Historical AGRX trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Narrow Range Bar Range Contraction 1.40%
    Older End-of-Day Signals for AGRX ...

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    AGRX Chart by TradingView
    Basic chart:

    Profile

    Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Pharmaceutical Drugs Alcohol Clinical Development Organic Compounds Estrogen Transdermal Estranes Hormonal Contraception Medroxyprogesterone Acetate

    Is AGRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Aug 26 Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
    Aug 12 Agile Therapeutics: Q2 Earnings Snapshot
    Jun 26 Agile Therapeutics to be acquired by Spain-based Insud for an enterprise value of ~$45M
    Jun 26 Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
    May 15 Agile Therapeutics Non-GAAP EPS of -$0.63, revenue of $5.7M
    May 15 Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    See more AGRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.0401
    52 Week Low 0.2
    Average Volume 306,745
    200-Day Moving Average 1.45
    50-Day Moving Average 0.55
    20-Day Moving Average 0.79
    10-Day Moving Average 1.22
    Average True Range 0.08
    RSI (14) 86.54
    ADX 53.69
    +DI 68.76
    -DI 4.77
    Chandelier Exit (Long, 3 ATRs) 1.23
    Chandelier Exit (Short, 3 ATRs) 0.57
    Upper Bollinger Bands 1.85
    Lower Bollinger Band -0.26
    Percent B (%b) 0.81
    BandWidth 266.56
    MACD Line 0.28
    MACD Signal Line 0.19
    MACD Histogram 0.0911
    Fundamentals Value
    Market Cap 4.3 Million
    Num Shares 2.96 Million
    EPS 7.31
    Price-to-Earnings (P/E) Ratio 0.20
    Price-to-Sales 0.18
    Price-to-Book 1.79
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.48
    Resistance 3 (R3) 1.48 1.47 1.48
    Resistance 2 (R2) 1.47 1.46 1.47 1.48
    Resistance 1 (R1) 1.46 1.46 1.46 1.46 1.47
    Pivot Point 1.45 1.45 1.45 1.45 1.45
    Support 1 (S1) 1.44 1.44 1.43 1.44 1.43
    Support 2 (S2) 1.43 1.44 1.43 1.42
    Support 3 (S3) 1.42 1.43 1.42
    Support 4 (S4) 1.42